Checchi Capital Advisers’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $701K | Buy |
1,570
+185
| +13% | +$86.3K | 0.04% | 274 |
|
|
2025
Q4 | $628K | Sell |
1,385
-76
| -5% | -$32.8K | 0.03% | 272 |
|
|
2025
Q3 | $572K | Sell |
1,461
-333
| -19% | -$139K | 0.03% | 296 |
|
|
2025
Q2 | $799K | Sell |
1,794
-41
| -2% | -$18.9K | 0.04% | 250 |
|
|
2025
Q1 | $890K | Buy |
1,835
+31
| +2% | +$14.4K | 0.05% | 229 |
|
|
2024
Q4 | $726K | Sell |
1,804
-13
| -0.7% | -$6.03K | 0.04% | 249 |
|
|
2024
Q3 | $845K | Buy |
1,817
+12
| +0.7% | +$5.76K | 0.05% | 222 |
|
|
2024
Q2 | $846K | Buy |
1,805
+118
| +7% | +$51.2K | 0.04% | 216 |
|
|
2024
Q1 | $705K | Buy |
1,687
+24
| +1% | +$10.1K | 0.06% | 254 |
|
|
2023
Q4 | $677K | Buy |
1,663
+22
| +1% | +$8.13K | 0.05% | 242 |
|
|
2023
Q3 | $571K | Sell |
1,641
-553
| -25% | -$193K | 0.05% | 255 |
|
|
2023
Q2 | $772K | Buy |
2,194
+485
| +28% | +$163K | 0.07% | 206 |
|
|
2023
Q1 | $538K | Buy |
1,709
+10
| +0.6% | +$3K | 0.05% | 272 |
|
|
2022
Q4 | $491K | Buy |
1,699
+116
| +7% | +$35.4K | 0.05% | 279 |
|
|
2022
Q3 | $458K | Buy |
1,583
+23
| +1% | +$6.62K | 0.04% | 284 |
|
|
2022
Q2 | $437K | Buy |
1,560
+130
| +9% | +$34.8K | 0.04% | 321 |
|
|
2022
Q1 | $373K | Buy |
1,430
+297
| +26% | +$70.5K | 0.03% | 344 |
|
|
2021
Q4 | $249K | Sell |
1,133
-103
| -8% | -$20K | 0.02% | 442 |
|
|
2021
Q3 | $224K | Sell |
1,236
-82
| -6% | -$16K | 0.02% | 453 |
|
|
2021
Q2 | $266K | Sell |
1,318
-81
| -6% | -$16.9K | 0.03% | 424 |
|
|
2021
Q1 | $301K | Sell |
1,399
-88
| -6% | -$19.3K | 0.03% | 355 |
|
|
2020
Q4 | $351K | Sell |
1,487
-222
| -13% | -$50.9K | 0.04% | 303 |
|
|
2020
Q3 | $465K | Buy |
1,709
+103
| +6% | +$28.4K | 0.05% | 215 |
|
|
2020
Q2 | $466K | Buy |
1,606
+208
| +15% | +$56.4K | 0.06% | 214 |
|
|
2020
Q1 | $333K | Sell |
1,398
-69
| -5% | -$15.8K | 0.03% | 236 |
|
|
2019
Q4 | $321K | Buy |
1,467
+8
| +0.5% | +$1.62K | 0.04% | 286 |
|
|
2019
Q3 | $247K | Buy |
1,459
+48
| +3% | +$8.49K | 0.03% | 342 |
|
|
2019
Q2 | $259K | Buy |
1,411
+231
| +20% | +$40.4K | 0.03% | 334 |
|
|
2019
Q1 | $217K | Sell |
1,180
-59
| -5% | -$10.9K | 0.03% | 365 |
|
|
2018
Q4 | $205K | Sell |
1,239
-360
| -23% | -$62.4K | 0.03% | 337 |
|
|
2018
Q3 | $308K | Buy |
1,599
+39
| +3% | +$6.95K | 0.04% | 311 |
|
|
2018
Q2 | $265K | Buy |
1,560
+144
| +10% | +$22.3K | 0.03% | 326 |
|
|
2018
Q1 | $231K | Buy |
1,416
+78
| +6% | +$12.7K | 0.03% | 354 |
|
|
2017
Q4 | $201K | Buy |
+1,338
| New | +$198K | 0.03% | 394 |
|
|
2016
Q3 | – | Sell |
-1,763
| Closed | -$152K | – | 1194 |
|
|
2016
Q2 | $152K | Buy |
1,763
+73
| +4% | +$6.31K | 0.02% | 425 |
|
|
2016
Q1 | $134K | Sell |
1,690
-291
| -15% | -$26.3K | 0.03% | 470 |
|
|
2015
Q4 | $249K | Buy |
+1,981
| New | +$239K | 0.06% | 276 |
|
|
2015
Q3 | – | Sell |
-1,629
| Closed | -$201K | – | 377 |
|
|
2015
Q2 | $201K | Buy |
+1,629
| New | +$205K | 0.05% | 339 |
|
Other funds holding VRTX
VCM
VPM
Checchi Capital Advisers's VRTX Position: Q1 2026 in Review
Checchi Capital Advisers increased its Vertex Pharmaceuticals (VRTX) stake by 13% in Q1 2026, buying an estimated $86.3K and bringing the position to 1,570 shares worth $701K. The position accounts for 0.04% of the portfolio, ranked #274.
Checchi Capital Advisers first reported a position in VRTX in Q2 2015 and has held it in 38 quarters since. The position peaked at $890K in Q1 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.
- Checchi Capital Advisers held 1,570 shares of Vertex Pharmaceuticals worth $701K as of Q1 2026.
- Checchi Capital Advisers bought 185 Vertex Pharmaceuticals shares in Q1 2026, an estimated $86.3K.
- Vertex Pharmaceuticals made up 0.04% of Checchi Capital Advisers's portfolio in Q1 2026, its #274 holding.
- Checchi Capital Advisers first reported a position in Vertex Pharmaceuticals in Q2 2015 and has held it in 38 quarters since.
- Checchi Capital Advisers's Vertex Pharmaceuticals position peaked at $890K in Q1 2025.
- 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.
Based on Checchi Capital Advisers's 13F filing for Q1 2026, filed 4 May 2026.